There is a growing awareness of the interconnection between sleep, stress, and mood. Often, all 3 need to be addressed in clinical practice. In this interview, pioneering integrative health researcher, pathologist, immunologist, and biochemist Russell Jaffe, MD, PhD, shares his physiology-first approach to tackling all 3 of these common clinical issues. He and his team have developed and validated personalized, proactive, predictive, primary prevention practices and protocols over the last four decades. Listeners will glean new ideas regarding lifestyle and targeted nutrients that can help with sleep, stress, and mood.
Russell M. Jaffe, MD, PhD, is CEO and chairman of PERQUE Integrative Health (PIH). He is considered one of the pioneers of integrative and regenerative medicine. Since inventing the world’s first single step amplified (ELISA) procedure in 1984, a process for measuring and monitoring all delayed allergies, Jaffe has continually sought new ways to help speed the transition from our current healthcare system’s symptom reactive model to a more functionally integrated, effective, and compassionate system. PIH is the outcome of years of Jaffe’s scientific research. It brings to market 3 decades of rethinking safer, more effective, novel, and proprietary dietary supplements, supplement delivery systems, diagnostic testing, and validation studies.
PERQUE Integrative Health (PIH) is dedicated to speeding the transition from sickness care to healthful caring. Delivering novel, personalized health solutions, PIH gives physicians and their patients the tools needed to achieve sustained optimal wellness. Combining the best in functional, evidence-based testing with premium professional supplements and healthful lifestyle guides, PIH solutions deliver successful outcomes in even the toughest cases. If you are interested in delving more deeply into this and other integrative health topics, we invite you to join the PIH Academy.
Additional resources made available to you by PIH and Jaffe are shown below:
Leanna Standish, ND, PhD, LAc, FABNO, discusses the clinical use of mind-altering drugs for addressing central nervous system conditions of all kinds in this interview with Editor-in-Chief Tina Kazcor, ND, FABNO. For more than 20 years, Standish has been advocating for a legal, standardized source of ayahuasca to study its effects properly in clinical trials. Her current clinical practice includes the use of ketamine-assisted psychotherapy to address deeply rooted causes of neurological and psychological conditions. In this interview, Standish covers the historical context and clinically relevant considerations for the use of psychedelics in practice.
Leanna J. Standish, ND, PhD, LAc, FABNO, is a neuroscientist and physician living in Seattle. She has faculty appointments in the University of Washington School of Medicine Radiology Department, the University of Washington School of Public Health, and Bastyr University. She is working toward obtaining approvals to conduct ayahuasca clinical studies in the United States. She uses functional magnetic brain imaging to study brain-to-brain communication and the ‘entangled minds’ hypothesis. As a physician she specializes in naturopathic oncology, with special interest in the treatment of stage 4 cancer.
Standish earned her PhD in neuroscience/biopsychology from the University of Massachusetts in 1978, her ND from Bastyr University in 1991, an MS in acupuncture and Oriental medicine from Bastyr University in 1994, and became board-certified in naturopathic oncology in 2006